Insys -18% following subpoena news

|About: Insys Therapeutics, Inc. (INSY)|By:, SA News Editor

Insys Therapeutics (INSY) -18.4% premarket following news it received a subpoena from the Department of Health and Human Services in connection with an investigation of potential violations involving HHS programs.

The subpoena requests documents regarding Subsys, including INSY's sales and marketing practices related to the product; Subsys, a sublingual spray to treat pain in opioid-tolerate cancer patients, is one of its INSY's two marketed products.